Arvinas (ARVN) Projected to Post Earnings on Tuesday

Arvinas (NASDAQ:ARVN) is expected to release its earnings data before the market opens on Tuesday, February 25th. Analysts expect Arvinas to post earnings of ($1.07) per share and revenue of $62.79 million for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same quarter last year, the company posted ($2.53) earnings per share. On average, analysts expect Arvinas to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Arvinas Stock Down 3.3 %

ARVN stock opened at $17.77 on Monday. The firm has a market cap of $1.22 billion, a PE ratio of -6.42 and a beta of 1.88. The business has a 50 day moving average of $18.49 and a 200-day moving average of $22.91. Arvinas has a 12-month low of $16.61 and a 12-month high of $51.51.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on ARVN shares. BMO Capital Markets reaffirmed an “outperform” rating and issued a $82.00 target price (down from $88.00) on shares of Arvinas in a report on Wednesday, February 12th. Cantor Fitzgerald reissued an “overweight” rating on shares of Arvinas in a report on Friday, February 7th. Barclays reduced their price objective on Arvinas from $48.00 to $32.00 and set an “overweight” rating for the company in a report on Monday, February 3rd. HC Wainwright reissued a “buy” rating and set a $87.00 price objective on shares of Arvinas in a report on Wednesday, December 11th. Finally, BTIG Research assumed coverage on Arvinas in a report on Tuesday, December 10th. They set a “buy” rating and a $69.00 price objective for the company. Twelve research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $60.00.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.